# Nanjing Kati Medical Technology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nanjing-kati-medical-technology

- Industry: Healthcare Specialists
- Headquarters: Nanjing, China
- Website: www.cart-med.com
- Total disclosed funding: $11M
- Latest round: Series A (Mar 9, 2022)
- Investors on record: 5

## About

Based in Nanjing, China, and established in 2017, Nanjing Kati Medical Technology aka CART is a medical company that develops solid tumor CAR-T cell therapy and immune cell therapy. In July 2017, the company established the CMP platform. In 2018, its first clinical trial for patients with solid tumors was started.

The company has formed dozens of product pipelines. Its R&D areas include DAP12 platform based CAR pipelines, CAR signal platform based on natural T cell receptors, CAR and TCR-T, lentivirus vectors, and CAR-T manufacturing.

## Funding rounds

- Series A, Mar 9, 2022, $11M — Asia View Capital, Hiway Capital, Cheng Yi Capital, Qiandao Group
- Series A, Mar 20, 2019 — YuanBio Venture

## Investors

- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series A
- Asia View Capital (https://capitalatlas.ai/funds/asia-view-capital) — Series A
- Hiway Capital (https://capitalatlas.ai/funds/hiway-capital) — Series A
- Cheng Yi Capital (https://capitalatlas.ai/funds/cheng-yi-capital) — Series A
- Qiandao Group — Series A